nach oben

Erschienen in:

24.01.2021 | Vorhofflimmern | Zertifizierte Fortbildung Neurologie

Sekundärpräventiver Nutzen versus Blutungsrisiko

Beginn der Antikoagulation nach akutem Schlaganfall

verfasst von: Dr. med. Gerrit M. Große, Prof. Dr. med. Christian Weimar, Prof. Dr. med. Hans-Christoph Diener

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Auszug

Bei bis zu 25-30 % aller ischämischen Schlaganfälle ist die Ursache eine kardiale Embolie bei Vorhofflimmern. Durch die orale Antikoagulation kann das Risiko für einen erneuten Schlaganfall deutlich gesenkt werden. Nach wie vor unklar ist jedoch, zu welchem Zeitpunkt nach einem akuten Ereignis mit der Antikoagulation begonnen werden sollte. Hierbei steht der sekundärpräventive Nutzen dem möglichen Blutungsrisiko und dabei insbesondere dem Risiko für eine intrazerebrale Blutung gegenüber. Sowohl das Risiko für eine erneute Ischämie als auch für eine sekundäre Hämorrhagie ist besonders in den ersten zwei Wochen nach dem initialen Ereignis erhöht. …

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67

Diener HC et al. Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 2020;22(Suppl I):I13-i21

Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2018;3(3):Cd008980

Salazar CA et al. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014(3):Cd009893

Seiffge DJ et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. The Lancet Neurology 2019;18(1):117-26

Diener HC, Ntaios G, O'Donnell M, Easton JD. Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke. Expert Opin Pharmacother 2018;19(14):1597-602

Tu HT et al. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. Int J Stroke 2015;10(4):534-40

Paciaroni M et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008;39(8):2249-56

Yaghi S et al. Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC study. J Neurol Neurosurg Psychiatry 2020;91(7):750-5

10.

Paciaroni M et al. Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. J Am Heart Assoc. 2018;7(22):e010133

11.

Marsh EB et al. Hemorrhagic transformation in patients with acute ischaemic stroke and an indication for anticoagulation. European Journal of Neurology. 2013;20(6):962-7

12.

Paciaroni M et al. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thrombosis and Haemostasis 2017;116(09):410-6

13.

Mac Grory B et al. Anticoagulation Resumption After Stroke from Atrial Fibrillation. Curr Atheroscler Rep. 2019;21(8):29

14.

Toyoda K et al. CHADS2 and CHA2DS2-VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study. Hypertens Res 2014;37(5):463-6

15.

Paciaroni M et al. Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. J Neurol 2016;263(2):231-7

16.

Yaghi S, Kamel H. Stratifying Stroke Risk in Atrial Fibrillation: Beyond Clinical Risk Scores. Stroke. 2017;48(10):2665-70

17.

Banerjee A et al. Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. Europace 2019;21(12):1776-84

18.

Paciaroni M et al. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke 2015;46(8):2175-82

19.

Paciaroni M et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc 2017;6(12)

20.

Yaghi S et al. Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk. Ann Neurol 2020;88(4):807-16.

21.

Wilson D et al. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J Neurol Neurosurg Psychiatry 2019;90(3):320-5

22.

Mizoguchi T et al. Early Initiation of Direct Oral Anticoagulants After Onset of Stroke and Short- and Long-Term Outcomes of Patients With Nonvalvular Atrial Fibrillation. Stroke 2020;51(3):883-91

23.

Paciaroni M et al. Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study. Stroke 2017;48(3):726-32

24.

Seiffge DJ et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol 2019;85(6):823-34

25.

Klijn CJ et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J 2019;4(3):198-223

26.

Powers WJ et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019;50(12):e344-e418

27.

Steffel J et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal 2018;39(16):1330-93

28.

Rybinnik I et al. Anticoagulation Choice and Timing in Stroke Due to Atrial Fibrillation: A Survey of US Stroke Specialists (ACT-SAFe). J Stroke Cerebrovasc Dis 2020;29(10):105169

29.

Munn D et al. A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation? Eur Stroke J 2018;3(4):355-60

30.

Groot AE et al. Continuation or Discontinuation of Anticoagulation in the Early Phase After Acute Ischemic Stroke. Stroke 2018;49(7):1762-5

31.

Whiteley WN et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol 2013;12(6):539-45

32.

Altavilla R et al. Anticoagulation After Stroke in Patients With Atrial Fibrillation. Stroke. 2019;50(8):2093-100

33.

Yaghi S et al. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. Stroke 2020;51(9): 2724-32

34.

Asberg S et al. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. Trials 2017;18(1):581

35.

King BT et al. Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial. International Journal of Stroke 2019;14(9):977-82

36.

Haas K et al. Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J 2019;4(2):181-8

Titel: Sekundärpräventiver Nutzen versus Blutungsrisiko
Beginn der Antikoagulation nach akutem Schlaganfall
verfasst von: Dr. med. Gerrit M. Große
Prof. Dr. med. Christian Weimar
Prof. Dr. med. Hans-Christoph Diener
Publikationsdatum: 24.01.2021
Verlag: Springer Medizin
Schlagwörter: Vorhofflimmern
Direkte orale Antikoagulanzien
Apoplex
Direkte orale Antikoagulanzien
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 1/2021
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-020-1784-5

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Leitsymptome erkennen, rechtzeitig behandeln, Funktion erhalten

DNRI verbessert Wachheit über den ganzen Tag anhaltend

Cannabinoide bei psychiatrischen Erkrankungen: stichhaltige Beweise fehlen

CME: Motivierende Gesprächsführung bei psychischen Erkrankungen

Impfen bei Multipler Sklerose erfordert sorgfältige Nutzen-Risiko-Abwägung

Delir als einziges Symptom von COVID-19